These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11329406)

  • 21. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.
    Shen YC; Chen SF; Chen CH; Lin CC; Chen SJ; Chen YJ; Luu SU
    J Psychiatr Res; 2009 Mar; 43(6):600-6. PubMed ID: 18926547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
    J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder.
    Chou JC; Douyon R; Czobor P; Volavka J; Cooper TB
    Psychiatry Res; 1998 Oct; 81(1):51-5. PubMed ID: 9829650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacogenetics and treatment response in schizophrenia].
    Moulier V; Januel D
    Encephale; 2007 Dec; 33(6):954-64. PubMed ID: 18789788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response.
    Reynolds GP; Yao Z; Zhang X; Sun J; Zhang Z
    Eur Neuropsychopharmacol; 2005 Mar; 15(2):143-51. PubMed ID: 15695058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia.
    Zahari Z; Teh LK; Ismail R; Razali SM
    Psychiatr Genet; 2011 Aug; 21(4):183-9. PubMed ID: 21206399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Present data and treatment schedule of aripiprazole in the treatment of schizophrenia].
    Limosin F; Azorin JM; Krebs MO; Millet B; Glikman J; Camus V; Crocq MA; Costentin J; Daléry J
    Encephale; 2008 Jan; 34(1):82-92. PubMed ID: 18514155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up].
    Askenazy F; Dor E; Benoit M; Dupuis G; Serret S; Myquel M; Seddiki Y
    Encephale; 2010 Feb; 36(1):46-53. PubMed ID: 20159196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
    Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
    Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug treatment of schizophrenic psychoses in puerperium].
    Olbrich HM; Martin P
    Nervenarzt; 1994 Jul; 65(7):482-5. PubMed ID: 7800093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment.
    Drago A; Giegling I; Schäfer M; Hartmann AM; Friedl M; Konte B; Möller HJ; De Ronchi D; Stassen HH; Serretti A; Rujescu D
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):887-94. PubMed ID: 22980146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmentation of haloperidol by ascorbic acid in phencyclidine intoxication.
    Giannini AJ; Loiselle RH; DiMarzio LR; Giannini MC
    Am J Psychiatry; 1987 Sep; 144(9):1207-9. PubMed ID: 3631319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impacts of dopamine D2 receptor polymorphism and antipsychotic dosage on dopamine supersensitivity psychosis in schizophrenia.
    Takase M; Kanahara N; Oda Y; Niitsu T; Watanabe H; Iyo M
    Schizophr Res; 2017 Dec; 190():182-183. PubMed ID: 28285026
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of haloperidol and chlorpromazine in the treatment of phencyclidine psychosis.
    Giannini AJ; Eighan MS; Loiselle RH; Giannini MC
    J Clin Pharmacol; 1984 Apr; 24(4):202-4. PubMed ID: 6725621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remoxipride in the treatment of psychoses.
    Eriksson L
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 May; 18(3):619-23. PubMed ID: 8078994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of patients with delirium.
    Tauscher J; Tauscher-Wisniewski S; Kasper S
    Am J Psychiatry; 2000 Oct; 157(10):1711. PubMed ID: 11007745
    [No Abstract]   [Full Text] [Related]  

  • 39. Functional neuroimaging and pharmacogenetic studies of clozapine's action at dopamine receptors.
    Kerwin RW; Pilowsky L; Munro J; Shaikh S; Gill M; Collier D
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():57-62. PubMed ID: 7961575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of phenylcyclohexylpyrrolidine (PHP) psychosis with haloperidol.
    Giannini AJ; Price WA; Loiselle RH; Malone DW
    J Toxicol Clin Toxicol; 1985; 23(2-3):185-9. PubMed ID: 4057312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.